Home>Topics>Stocks>Onyx Pharmaceuticals

Onyx Pharmaceuticals ONXX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. SEC lawsuit over Onyx insider trading can move forward -U.S. judge

      Headlines

      Mon, 29 Sep 2014

      NEW YORK, Sept 29 (Reuters) - U.S. securities regulators can move forward with a lawsuit accusing two Dubai residents of making $3.7 million through insider trading in Onyx Pharmaceuticals Inc and...

    2. Biotech IPOs: What to Learn from a Banner Year

      Headlines

      Thu, 23 Jan 2014

      huge sums for smaller innovators. For example, last summer, Amgen upped its offer to buy cancer drug maker Onyx Pharmaceuticals from $9.3 billion to $9.7 billion. Such deals — along with generally healthy balance sheets and access to capital among life sciences companies

    3. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER:VRTX] Onyx Pharmaceuticals , has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been

      Onyx Pharmaceuticals found at 1:09

      multiple sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER:VRTX] Onyx Pharmaceuticals , has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been a company that
    4. Our Outlook for the Credit Markets

      Headlines

      Wed, 25 Sep 2013

      with its internal prospects last quarter when it decided to make the $10 billion debt-funded acquisition of Onyx Pharmaceuticals ONXX (rating: SUS, no moat). This acquisition will boost Amgen's top-line growth by nearly 200 basis points

    5. Onyx deal expected to give Amgen a big boost

      Headlines

      Mon, 26 Aug 2013

      Aug 26 (Reuters) - Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood...

    6. Reasonably Priced Onyx Acquisition Is Positive Strategic Move for Amgen; Maintain Wide Moat Rating

      Commentary

      Mon, 26 Aug 2013

      After several weeks of media speculation, Amgen finally announced the acquisition of Onyx Pharmaceuticals for $125 per share, valuing the company at $10.4 billion (or $9.7 billion net of cash). As we stated previously, we

    7. Amgen seeks drug trial data before finalizing Onyx deal: sources

      Headlines

      Thu, 15 Aug 2013

      NEW YORK (Reuters) - Amgen Inc, the drugmaker in advanced discussions to buy Onyx Pharmaceuticals Inc, has asked Onyx for some of the data from an ongoing trial on the company's new blood cancer...

    8. Deals of the day -- mergers and acquisitions

      Headlines

      Wed, 7 Aug 2013

      (Adds Onyx Pharmaceuticals , Telediffusion de France, TPG Capital and others)

    9. Well-timed options bets on Onyx Pharmaceuticals deliver pay-off

      Headlines

      Mon, 1 Jul 2013

      (Reuters) - Some options traders appeared to have scored a win with well-timed bullish bets on Onyx Pharmaceuticals before a rival made an unsolicited bid for the cancer drug maker.

    10. Amgen and Onyx a Logical Fit; Competing Bids Likely to Offer Upside to Initial Bid

      Commentary

      Mon, 1 Jul 2013

      Onyx ONXX confirmed on Sunday that it had received an unsolicited bid from Amgen AMGN of $120 per share, a 38% premium to Friday's close

    « Prev12345Next »
    Content Partners